GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 174 filers reported holding GENMAB A/S in Q2 2020. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,616 | -16.0% | 73,813 | +0.2% | 0.06% | -11.9% |
Q2 2023 | $3,113 | +22.8% | 73,678 | +9.8% | 0.07% | +11.7% |
Q1 2023 | $2,534 | -1.3% | 67,104 | +10.8% | 0.06% | -6.2% |
Q4 2022 | $2,567 | -99.9% | 60,559 | -4.6% | 0.06% | +12.3% |
Q3 2022 | $2,039,000 | +1.7% | 63,483 | +2.9% | 0.06% | +9.6% |
Q2 2022 | $2,004,000 | -8.3% | 61,670 | +2.1% | 0.05% | +6.1% |
Q1 2022 | $2,185,000 | -5.6% | 60,400 | +3.3% | 0.05% | -2.0% |
Q4 2021 | $2,314,000 | -2.4% | 58,490 | +7.7% | 0.05% | -10.7% |
Q3 2021 | $2,372,000 | +12.4% | 54,290 | +5.1% | 0.06% | +12.0% |
Q2 2021 | $2,110,000 | +13.3% | 51,680 | -8.9% | 0.05% | +8.7% |
Q1 2021 | $1,863,000 | -21.7% | 56,740 | -3.1% | 0.05% | -23.3% |
Q4 2020 | $2,380,000 | +10.9% | 58,545 | -0.2% | 0.06% | 0.0% |
Q3 2020 | $2,147,000 | +7.6% | 58,635 | -0.4% | 0.06% | +3.4% |
Q2 2020 | $1,995,000 | +77.2% | 58,875 | +10.8% | 0.06% | +45.0% |
Q1 2020 | $1,126,000 | +14.1% | 53,160 | +20.3% | 0.04% | +48.1% |
Q4 2019 | $987,000 | – | 44,200 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 52,148 | $1,839,260 | 1.67% |
Ativo Capital Management LLC | 28,442 | $1,003,132 | 1.13% |
HARDING LOEVNER LP | 3,204,230 | $113,013,183 | 0.75% |
Hardman Johnston Global Advisors LLC | 592,318 | $20,891,056 | 0.70% |
Yorktown Management & Research Co Inc | 16,600 | $585,482 | 0.66% |
TORRAY INVESTMENT PARTNERS LLC | 104,516 | $3,686,279 | 0.65% |
First Light Asset Management, LLC | 157,147 | $5,542,575 | 0.53% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,300 | $1,561,575 | 0.53% |
Capricorn Fund Managers Ltd | 37,007 | $1,305,237 | 0.45% |
Legacy Wealth Asset Management, LLC | 29,496 | $1,040,324 | 0.38% |